SVR Achieved With Sofosbuvir, Grazoprevir/Elbasvir Plus Ribavirin in HCV

HCV, Hepatitis, microscopic
HCV, Hepatitis, microscopic
Safety and efficacy of sofosbuvir plus grazoprevir/elbasvir plus ribavirin was evaluated in individuals who did not achieve sustained virological response on NS5A or NS3-based therapy and RAS failure.

According to the results of a recent study published in Clinical Infectious Diseases, individuals with hepatitis C who previously failed to achieve sustained virologic response (SVR) following treatment with direct-acting antivirals were shown to achieve SVR following a 16- or 24-week regimen of sofosbuvir and grazoprevir/elbasvir with ribavirin.

In the ANRS HC34 REVENGE trial, individuals with hepatitis C (genotypes 1 or 4) who had previously failed to achieve SVR following NS5A- or NS3-based therapy were randomly assigned to receive 16 or 24 weeks of sofosbuvir plus grazoprevir/elbasvir with ribavirin. Most patients had resistance-associated substitutions at failure, and many patients had advanced fibrosis or compensated cirrhosis. The primary outcome was SVR at 12 weeks.

Of the 26 patients included in the study, all had RNA below the lower limit of quantification at the end of treatment. A total of 25 of 26 patients achieved SVR at 12 weeks.

The patient who did not achieve SVR died 5 weeks after stopping treatment, but this patient had negative HCV RNA at that time.

Treatment was well tolerated, with no severe treatment-related adverse events.

The study authors noted that, “16 or 24 weeks of the combination of sofosbuvir + grazoprevir/elbasvir + ribavirin yields SVR in 100% of cases. Thus, 16 weeks of this combination appears as a reasonable and safe option for retreatment of patients exposed to [direct-acting antivirals] and who failed to achieve SVR, especially those with NS5A inhibitor-resistant viruses.”

Related Articles


de Lédinghen V, Laforest C, Hézode C, et al. Retreatment with sofosbuvir plus grazoprevir/elbasvir plus ribavirin of patients with hepatitis C virus genotype 1 or 4 who previously failed a NS5A or NS3-containing regimen. ANRS HC34 REVENGE [published online October 25, 2017]. Clin Infect Dis. doi:10.1093/cid/cix916